OncoMatch/Clinical Trials/NCT06798363

Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma

Is NCT06798363 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies propranolol for infantile hemangioma.

Phase 2/3RecruitingWest China HospitalNCT06798363Data as of May 2026

Treatment: propranolol — The main objective of this study was to determine the efficacy of different doses of propranolol in the treatment of ulcerattion infantile hemangioma (IH).

Check if I qualify

Extracted eligibility criteria

Prior therapy

Cannot have received: other therapeutic interventions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify